DSPVG Acquisition Subs
A dedicated, ring-fenced entity for each life sciences service business acquisition
DSPVG Acquisition Subs (the “Acquisition Sub”) are the special-purpose entities used to originate, structure, and close each acquisition before rolling stabilized assets into the appropriate DSPVG vertical HoldCo (spoke). This SPE per business acquisition structure, isolates risk, accelerates diligence & financing, and provides sellers and capital partners confidence in a clean, bank-ready close.
What the Acquisition Sub Does (At a Glance)
Closes transactions efficiently
Streamlined process from indication of interest (IOI) → letter of intent (LOI) → confirmatory diligence → close.
Protects counterparties
Ring-fenced liabilities, no co-mingling, clean capitalization, and diligence-ready documentation. Structured to support insurer- and lender-friendly transaction mechanics where appropriate.
Delivers financing certainty
Preference for 100% equity solutions where speed and certainty matter, with flexibility for structured stacks (management rollover, earn-outs, seller notes) when aligned with the transaction.
Prepares integration
Day-one controls across quality, finance, and data governance—then transition into the right DSPVG HoldCo with clear accountability, reporting cadence, and operating standards.
What we buy
EBITDA
$1–10M with clean financials
(Typical focus: platform anchors $2–5M; add-ons $1–3M.)
Revenue quality
Recurring/retainer/MSA-based revenue with multi-year frameworks preferred.
Defensible moat
Compliance-critical workflows such as:
• Regulatory operations (e.g., submissions support, inspection readiness)
• Digital quality systems (eQMS, CAPA, audit readiness)
• Validation (CSV/CSA, IQ/OQ/PQ)
Pharmacovigilance and safety operations
ESG/EHS reporting and compliance enablement (including SustainEnvi-aligned capabilities)
Quality posture
Active SOPs, a functioning training matrix, and an audit posture that can integrate into centralized Quality & Compliance governance and a unified eQMS.
Operating fit
Low-capex delivery model, standardized service lines, compatible toolsets, and scalable execution.
Customer concentration
Top client under 30% of revenue preferred, or a clear and credible diversification pathway.
People-first continuity
Management and staff are invited to stay. We invest in leadership continuity and capability-building.
Adjacency and cross-sell path
Clear opportunity to cross-sell into at least one additional DSPVG spoke within 6–12 months.
What We Pass On
• One-off bespoke consultancies without repeatable delivery models
• Businesses with primary value tied to unproven scientific outcomes (science risk)
• Capex-heavy manufacturing models that do not match our compliance-services thesis
Our 90-Day and 12-Month Playbooks
First 90 Days Post-Close
• Map top 20 accounts and adjacency opportunities; assign executive sponsors
• Harmonize rate cards and align to a single MSA / multi-SOW commercial framework
• Launch “Good / Better / Best” bundles; pilot two-service cross-sell motions with priority accounts
• Stand up sponsor-visible dashboards (examples: submission timeliness, ICSR on-time performance, eTMF completeness, cold-chain exception tracking, CAPA aging)
By 12 Months — TARGETS
• Cross-sold revenue mix and utilization improvement supported by bundling and standardized delivery
• Margin improvement through shared services and unified audit readiness
• Options preserved for recapitalization, spoke-level sale, or larger platform
combination—depending on market conditions and strategic fit
Investors
Join as an anchor equity partner for the platform close and initial add-ons, with co-investment rights across the buy-and-build program.